Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function

Yu‐Jen Chen(Taipei Medical University), Shih‐Hsien Sung(National Yang Ming Chiao Tung University), Hao‐Min Cheng(National Yang Ming Chiao Tung University), Wei‐Ming Huang(National Yang Ming Chiao Tung University), Chung‐Li Wu(Taipei Veterans General Hospital), Chi‐Jung Huang(Taipei Veterans General Hospital), Pai‐Feng Hsu(National Yang Ming Chiao Tung University), Jong‐Shiuan Yeh(Taipei Medical University), Chao‐Yu Guo(National Yang Ming Chiao Tung University), Wen‐Chung Yu(National Yang Ming Chiao Tung University), Chen‐Huan Chen(National Yang Ming Chiao Tung University)
Journal of the American Heart Association
May 1, 2017
Cited by 42Open Access
Full Text

Abstract

BACKGROUND: AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) score has been related to clinical outcomes of acute heart failure. However, the prognostic value of the AHEAD score in acute heart failure patients with either reduced or preserved left ventricular ejection fraction (HFrEF and HFpEF) remain to be elucidated. METHODS AND RESULTS: The study population consisted of 2143 patients (age 77±12 years, 68% men, 38% HFrEF) hospitalized primarily for acute heart failure with a median follow-up of 23.75 months. The performance of the AHEAD score (atrial fibrillation, hemoglobin <13 mg/dL for men and 12 mg/dL for women, age >70 years, creatinine >130 μmol/L, and diabetes mellitus) was evaluated by Cox's regression analysis for predicting cardiovascular and all-cause mortality. The mean AHEAD scores were 2.7±1.2 in the total study population, 2.6±1.3 in the HFrEF group, and 2.7±1.1 in the HFpEF group. After accounting for sex, sodium, uric acid, and medications, the AHEAD score remained significantly associated with all-cause and cardiovascular mortality (hazard ratio and 95% CI: 1.49, 1.38-1.60 and 1.48, 1.33-1.64), respectively. The associations of AHEAD score with mortality remained significant in the subgroups of HFrEF (1.63, 1.47-1.82) and HFpEF (1.34, 1.22-1.48). Moreover, when we calculated a new AHEAD-U score by considering uric acid (>8.6 mg/dL) in addition to the AHEAD score, the net reclassification was improved by 19.7% and 20.1% for predicting all-cause and cardiovascular mortality, respectively. CONCLUSIONS: The AHEAD score was useful in predicting long-term mortality in the Asian acute heart failure cohort with either HFrEF or HFpEF. The new AHEAD-U score may further improve risk stratification.


Related Papers

No related papers found

Powered by citation graph analysis